The Cellular Response to Oxidatively Induced DNA Damage and Polymorphism of Some DNA Repair Genes Associated with Clinicopathological Features of Bladder Cancer

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Savina, Nataliya V ^a   Nikitchenko, Nataliya V ^a   Kuzhir, Tatyana D ^a   Rolevich, Alexander I ^b   Krasny, Sergei A ^b   Goncharova, Roza I ^a  

^a INSTITUTE OF GENETICS AND CYTOLOGY   (Belarus)

^b NN Alexandrov National Cancer Center of Belarus   (Belarus)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; DNA; DNA SEQUENCES; GENES; MUSCLE; PATHOLOGY; POLYMERASE CHAIN REACTION; TUMORS;

ALKALINE COMET ASSAY; BASE EXCISION REPAIRS; CANCER PROGRESSION; CELLULAR RESPONSE; CHRONIC INFLAMMATION; DNA DAMAGE RESPONSE; GENOME INSTABILITY; NUCLEOTIDE EXCISION REPAIR;

REPAIR;

8 OXOGUANINE DNA GLYCOSYLASE 1; DNA; DNA GLYCOSYLTRANSFERASE; EXCISION REPAIR PROTEIN ERCC6; HYDROGEN PEROXIDE; PROTEIN; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; DNA HELICASE; DNA LIGASE; ERCC2 PROTEIN, HUMAN; ERCC6 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; BELARUSIAN (PEOPLE); BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER RISK; CLINICAL FEATURE; COMET ASSAY; CONTROLLED STUDY; DISEASE SEVERITY; DNA DAMAGE; DNA REPAIR; EXCISION REPAIR; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; OXIDATIVE STRESS; PERIPHERAL LYMPHOCYTE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; WILD TYPE; BLADDER TUMOR; GENETICS; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TUMOR INVASION;

ADULT; DNA DAMAGE; DNA HELICASES; DNA REPAIR; DNA REPAIR ENZYMES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; OXIDATION-REDUCTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; URINARY BLADDER NEOPLASMS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84948807584     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/5710403     Document Type: Article

References (71)

1. C. Streffer, "Strong association between cancer and genomic instability," Radiation and Environmental Biophysics, vol. 49, no. 2, pp. 125-131, 2010.
2. M. Dizdaroglu, "Oxidatively induced DNA damage: mechanisms, repair and disease," Cancer Letters, vol. 327, no. 1-2, pp. 26-47, 2012.
3. S. Bonassi, H. Norppa, M. Ceppi et al., "Chromosomal aberration frequency in lymphocytes predicts the risk of cancer: results from a pooled cohort study of 22 358 subjects in 11 countries," Carcinogenesis, vol. 29, no. 6, pp. 1178-1183, 2008.
4. S. Bonassi, R. El-Zein, C. Bolognesi, and M. Fenech, "Micronuclei frequency in peripheral blood lymphocytes and cancer risk: evidence from human studies," Mutagenesis, vol. 26, no. 1, pp. 93-100, 2011.
5. A. A. G. van Tilborg, A. de Vries,M. de Bont, L. E. Groenfeld, T. H. van der Kwast, and E. C. Zwarthoff, "Molecular evolution of multiple recurrent cancers of the bladder," Human Molecular Genetics, vol. 9, no. 20, pp. 2973-2980, 2000.
6. J. Bartkova, Z. Horejs̈, K. Koed et al., "DNAdamage response as a candidate anti-cancer barrier in early human tumorigenesis," Nature, vol. 434, no. 7035, pp. 864-870, 2005.
7. T. K. Hazra, A. Das, S. Das, S. Choudhury, Y. W. Kow, and R. Roy, "Oxidative DNA damage repair inmammalian cells: a new perspective," DNA Repair, vol. 6, no. 4, pp. 470-480, 2007.
8. A. Campalans, S. Marsin, Y. Nakabeppu, T. R. O'Connor, S. Boiteux, and J. P. Radicella, "XRCC1 interactions with multiple DNA glycosylases: a model for its recruitment to base excision repair," DNA Repair, vol. 4, no. 7, pp. 826-835, 2005.
9. B. R. Berquist, D. K. Singh, J. Fan et al., "Functional capacity of XRCC1 protein variants identified in DNA repair-deficient Chinese hamster ovary cell lines and the human population," Nucleic Acids Research, vol. 38, no. 15, pp. 5023-5035, 2010.
10. E. Markkanen, R. Fischer, M. Ledentcova, B. M. Kessler, and G. L. Dianov, "Cells deficient in base-excision repair reveal cancer hallmarks originating from adjustments to genetic instability," Nucleic Acids Research, vol. 43, no. 7, pp. 3667-3679, 2015.
11. J. H. J. Hoeijmakers, "Genome maintenance mechanisms for preventing cancer," Nature, vol. 411, no. 6835, pp. 366-374, 2001.
12. S. C. Shuck, E. A. Short, and J. J. Turchi, "Eukaryotic nucleotide excision repair: fromunderstandingmechanisms to influencing biology," Cell Research, vol. 18, no. 1, pp. 64-72, 2008.
13. J. Kuper and C. Kisker, "DNA helicases in NER, BER, and MMR," Advances in Experimental Medicine and Biology, vol. 767, pp. 203-224, 2013.
14. J. O. Fuss and J. A. Tainer, "XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase," DNA Repair, vol. 10, no. 7, pp. 697-713, 2011.
15. J. C. Newman, A. D. Bailey, and A. M. Weiner, "Cockayne syndrome group B protein (CSB) plays a general role in chromatin maintenance and remodeling," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 25, pp. 9613-9618, 2006.
16. R. J. Lake and Y. H. Fan, "Structure, function and regulation of CSB: a multi-talented gymnast," Mechanisms of Ageing and Development, vol. 134, no. 5-6, pp. 202-211, 2013.
17. M. Fousteri and L. H. F. Mullenders, "Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects," Cell Research, vol. 18, no. 1, pp. 73-84, 2008.
18. R. Vélez-Cruz and J.-M. Egly, "Cockayne syndrome group B (CSB) protein: at the crossroads of transcriptional networks," Mechanisms of Ageing and Development, vol. 134, no. 5-6, pp. 234-242, 2013.
19. H. Menoni, J. H. J. Hoeijmakers, and W. Vermeulen, "Nucleotide excision repair-initiating proteins bind to oxidative DNA lesions in vivo," Journal of Cell Biology, vol. 199, no. 7, pp. 1037-1046, 2012.
20. E. Parlanti,M. D'Errico, P. Degan et al., "The cross talk between pathways in the repair of 8-oxo-7,8-dihydroguanine in mouse and human cells," FreeRadical Biology andMedicine, vol. 53, no. 11, pp. 2171-2177, 2012.
21. V. P. Ramaniuk, N. V. Nikitchenko, N. V. Savina et al., "Polymorphism of DNA repair genes OGG1, XRCC1, XPD and ERCC6 in bladder cancer in Belarus," Biomarkers, vol. 19, no. 6, pp. 509-516, 2014.
22. M. Babjuk, W. Oosterlinck, R. Sylvester et al., "EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update," European Urology, vol. 59, no. 6, pp. 997-1008, 2011.
23. A. Stenzl, N. C. Cowan, M. De Santis et al., "The updated EAU guidelines on muscle-invasive and metastatic bladder cancer," European Urology, vol. 55, no. 4, pp. 815-825, 2009.
24. World Medical Association, "World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects," in Proceedings of the 18th WMA General Assembly, Helsinki, Finland, June 1964, http://www. wma. net/en/30publications/10policies/b3/index. html.
25. N. V. Savina, M. P. Smal, T. D. Kuzhir et al., "Chromosomal instability at the 7q11. 23 region impacts on DNA-damage response in lymphocytes from Williams-Beuren syndrome patients," Mutation Research/Genetic Toxicology and Environmental Mutagenesis, vol. 724, no. 1-2, pp. 46-51, 2011.
26. N. V. Savina, M. P. Smal, T. D. Kuzhir et al., "Biomarkers for genome instability in some genetic disorders: a pilot study," Biomarkers, vol. 17, no. 3, pp. 201-208, 2012.
27. N. V. Savina, M. P. Smal, T. D. Kuzhir, A. A. Ershova-Pavlova, and R. I. Goncharova, "DNA-damage response associated with occupational exposure, age and chronic inflammation in workers in the automotive industry," Mutation Research-Genetic Toxicology and Environmental Mutagenesis, vol. 748, no. 1-2, pp. 21-28, 2012.
28. R. R. Tice, E. Agurell, D. Anderson et al., "Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing," Environmental and Molecular Mutagenesis, vol. 35, no. 3, pp. 206-221, 2000.
29. A. R. Collins, I. M. Fleming, and C. M. Gedik, "In vitro repair of oxidative and ultraviolet-induced DNA damage in supercoiled nucleoid DNA by human cell extract," Biochimica et Biophysica Acta, vol. 1219, no. 3, pp. 724-727, 1994.
30. M. R. Spitz, X. Wu, Y. Wang et al., "Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients," Cancer Research, vol. 61, no. 4, pp. 1354-1357, 2001.
31. C.-H. Chang, C.-F. Chiu, H.-C. Wang et al., "Significant association of ERCC6 single nucleotide polymorphisms with bladder cancer susceptibility in Taiwan," Anticancer Research, vol. 29,no. 12, pp. 5121-5124, 2009.
32. T. D. Kuzhir, N. V. Savina, A. A. Ershova-Pavlova et al., "Assessment of the genome integrity in lymphocytes of people engaged in industry," Doklady of the National Academy of Sciences of Belarus, vol. 56, no. 4, pp. 72-76, 2012 (Russian).
33. S. Jankovíc and V. Radosavljevíc, "Risk factors for bladder cancer," Tumori, vol. 93, no. 1, pp. 4-12, 2007.
34. M. Franekova, E. Halasova, E. Bukovska, J. Luptak, and D. Dobrota, "Gene polymorphisms in bladder cancer," Urologic Oncology: Seminars and Original Investigations, vol. 26, no. 1, pp. 1-8, 2008.
35. V. P. Ramaniuk, N. V. Nikitchenko, N. V. Savina, T. D. Kuzhir, and R. I. Goncharova, "Polymorphism of excision repair genes XPD, XRCC1, and hOGG1 in the population of the republic of Belarus and its impact on carcinogenesis," Russian Journal of Genetics: Applied Research, vol. 5, no. 2, pp. 141-154, 2015.
36. P. Moller, "Genotoxicity of environmental agents assessed by the alkaline comet assay," Basic and Clinical Pharmacology and Toxicology, vol. 96, no. 1, pp. 1-42, 2005.
37. M. Dusinska and A. R. Collins, "The comet assay in human biomonitoring: gene-environment interactions," Mutagenesis, vol. 23, no. 3, pp. 191-205, 2008.
38. W. W. Au, A. K. Giri, and M. Ruchirawat, "Challenge assay: a functional biomarker for exposure-induced DNA repair deficiency and for risk of cancer," International Journal of Hygiene and Environmental Health, vol. 213, no. 1, pp. 32-39, 2010.
39. S. M. Piperakis, K. Kontogianni, G. Karanastasi, Z. Iakovidou-Kritsi, and M. M. Piperakis, "The use of comet assay in measuring DNA damage and repair efficiency in child, adult, and old age populations," Cell Biology and Toxicology, vol. 25, no. 1, pp. 65-71, 2009.
40. J. E. Klaunig, L. M. Kamendulis, and B. A. Hocevar, "Oxidative stress and oxidative damage in carcinogenesis," Toxicologic Pathology, vol. 38, no. 1, pp. 96-109, 2010.
41. J. S. Dawane and V. A. Pandit, "Understanding redox homeostasis and its role in cancer," Journal of Clinical and Diagnostic Research, vol. 6, no. 10, pp. 1796-1802, 2012.
42. C. Li and H.-M. Zhou, "The role of manganese superoxide dismutase in inflammation defense," Enzyme Research, vol. 2011, Article ID 387176, 6 pages, 2011.
43. S. Hoffman, J. Nolin, D. McMillan, E. Wouters, Y. Janssen-Heininger, and N. Reynaert, "Thiol redox chemistry: role of protein cysteine oxidation and altered redox homeostasis in allergic inflammation and asthma," The Journal of Cellular Biochemistry, vol. 116, no. 6, pp. 884-892, 2015.
44. J. Rybka, D. Kupczyk, K. Kdziora-Kornatowska et al., "Agerelated changes in an antioxidant defense system in elderly patients with essential hypertension compared with healthy controls," Redox Report, vol. 16, no. 2, pp. 71-77, 2011.
45. S. Haider, S. Saleem, T. Perveen et al., "Age-related learning and memory deficits in rats: role of altered brain neurotransmitters, acetylcholinesterase activity and changes in antioxidant defense system," Age, vol. 36, no. 3, pp. 1291-1302, 2014.
46. H. Bartsch and J. Nair, "Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair," Langenbeck's Archives of Surgery, vol. 391, no. 5, pp. 499-510, 2006.
47. J. K. Kundu and Y.-J. Surh, "Inflammation: gearing the journey to cancer," Mutation Research/Reviews in Mutation Research, vol. 659, no. 1-2, pp. 15-30, 2008.
48. S. Ohnishi, N. Ma, R. Thanan et al., "DNA damage in inflammation-related carcinogenesis and cancer stem cells," Oxidative Medicine and Cellular Longevity, vol. 2013,Article ID 387014, 9 pages, 2013.
49. A. R. Lehmann, "The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases," Genes and Development, vol. 15, no. 1, pp. 15-23, 2001.
50. J. E. Cleaver, A. M. Brennan-Minnella, R. A. Swanson et al., "Mitochondrial reactive oxygen species are scavenged by Cockayne syndrome B protein in human fibroblasts without nuclear DNA damage," Proceedings of the National Academy of Sciences of theUnited States ofAmerica, vol. 111, no. 37, pp. 13487-13492, 2014.
51. A. Khobta and B. Epe, "Repair of oxidatively generated DNA damage in Cockayne syndrome," Mechanisms of Ageing and Development, vol. 134, no. 5-6, pp. 253-260, 2013.
52. K. De Ruyck, M. Szaumkessel, I. De Rudder et al., "Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk," Mutation Research, vol. 631, no. 2, pp. 101-110, 2007.
53. M. Huang, C. P. Dinney, X. Lin, J. Lin, H. B. Grossman, and X. Wu, "High-order interactions among genetic variants in DNA base excision repair pathway genes and smoking in bladder cancer susceptibility," Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 1, pp. 84-91, 2007.
54. P. Storz, "Reactive oxygen species in tumor progression," Frontiers in Bioscience, vol. 10, no. 2, pp. 1881-1896, 2005.
55. G.-Y. Liou and P. Storz, "Reactive oxygen species in cancer," Free Radical Research, vol. 44, no. 5, pp. 479-496, 2010.
56. B. W. G. van Rhijn, T. H. van der Kwast, A. N. Vis et al., "FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma," Cancer Research, vol. 64, no. 6, pp. 1911-1914, 2004.
57. M. P. Smal, A. I. Rolevich, S. L. Polyakov, S. A. Krasny, and R. I. Goncharova, "FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients," Experimental Oncology, vol. 36, no. 4, pp. 246-251, 2014.
58. D. Lindgren, A. Frigyesi, S. Gudjonsson et al., "Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome," Cancer Research, vol. 70, no. 9, pp. 3463-3472, 2010.
59. X. Li, J. Chen, X. Hu et al., "Comparative mRNA and microrna expression profiling of three genitourinary cancers reveals common hallmarks and cancer-specificmolecular events," PLoS ONE, vol. 6, no. 7,Article ID e22570, 2011.
60. G. Guo, X. Sun, C. Chen et al., "Whole-genome and wholeexome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation," Nature Genetics, vol. 45, no. 12, pp. 1459-1463, 2013.
61. C. D. Morrison, P. Liu, A. Woloszynska-Read et al., "Wholegenome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer," Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 6, pp. E672-E681, 2014.
62. J. B. Cazier, S. R. Rao, C. M. McLean et al., "Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden," Nature Communications, vol. 5, p. 3756, 2014.
63. The Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of urothelial bladder carcinoma," Nature, vol. 507, no. 7492, pp. 315-322, 2014.
64. K. Golka, S. Selinski,M.-L. Lehmann et al., "Genetic variants in urinary bladder cancer: Collective power of the 'wimp SNPs'," Archives of Toxicology, vol. 85, no. 6, pp. 539-554, 2011.
65. M. Sasaki, S. Sakano, N. Okayama et al., "DNA repair gene polymorphisms may be associated with prognosis of upper urinary tract transitional cell carcinoma," Neoplasia, vol. 10, no. 3, pp. 255-265, 2008.
66. S. Sanyal, P. J. De Verdier, G. Steineck et al., "Polymorphisms in XPD, XPC and the risk of death in patients with urinary bladder neoplasms," Acta Oncologica, vol. 46, no. 1, pp. 31-41, 2007.
67. C. Sacerdote, S. Guarrera, F. Ricceri et al., "Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treatedwith chemotherapy," International Journal ofCancer, vol. 133, no. 8, pp. 2004-2009, 2013.
68. Y.-S. Ha, C. Yan, I. Y. Kim, S.-J. Yun, S.-K. Moon, andW.-J. Kim, "Tissue hOGG1 genotype predicts bladder cancer prognosis: a novel approach using a peptide nucleic acid clamping method," Annals of Surgical Oncology, vol. 18, no. 6, pp. 1775-1781, 2011.
69. J. Gu, H. Zhao, C. P. Dinney et al., "Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer," Clinical Cancer Research, vol. 11, no. 4, pp. 1408-1415, 2005.
70. R. D. Mittal, R. Singh, P. K. Manchanda et al., "XRCC1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinomain patients on BCGimmunotherapy," Cancer Biology andTherapy, vol. 7, no. 5, pp. 645-650, 2008.
71. K. F. Narter, A. Ergen, B. Agachan, U. Görmüs, O. Timirci, and T. Isbir, "Bladder cancer and polymorphisms of DNA repair genes (XRCC1, XRCC3, XPD, XPG, APE1, hOGGl)," Anticancer Research, vol. 29, no. 4, pp. 1389-1394, 2009.